Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment

Last updated: April 4, 2025
Sponsor: Fatima Maqsood
Overall Status: Completed

Phase

N/A

Condition

Chest Pain

Heart Failure

Diabetes And Hypertension

Treatment

Empagliflozin 10 MG OD

Dapagliflozin 10 mg daily

Clinical Study ID

NCT06915870
271
  • Ages 40-60
  • All Genders

Study Summary

Participants were enrolled and randomly divided in two groups. In group A, participants were prescribed Dapagliflozin 10 mg daily. In group B, participants were prescribed Empagliflozin 10 mg daily. All participants were followed-up in OPD after 12 weeks for assessment of ejection fraction.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients aged 40-60 years of either gender diagnosed with heart failure ( Heartfailure was defined as presence of ejection fraction <50% on echocardiography, withpedal edema, water in lungs, paroxysmal nocturnal dyspnea or exertional limitationdue to failure of ventricular fillings)

  • Diabetic patients, with HBA1c>6.5% for >1 year already taking SGLT-2 and ARNIinhibitor.

Exclusion

Exclusion Criteria:

  • Patients already had valvular device, mitral or aortic valve regurgitation orstenosis detected on echocardiography, heart transplantation, chronic renal failureor dialysis patients, cardiomyopathy, liver failure or malignancy.

  • Patients already taking trial drugs or other anti-glycemic or cardiac medication.

Study Design

Total Participants: 108
Treatment Group(s): 2
Primary Treatment: Empagliflozin 10 MG OD
Phase:
Study Start date:
July 12, 2024
Estimated Completion Date:
January 13, 2025

Study Description

This study's rationale is to examine the effects of dapagliflozin and empagliflozin on heart failure in patients receiving ARNI and SGLT2. Research revealed that the two medications results are identical. Although the cardiac functioning improved better with empagliflozin. But limited data has been available in this regard, while no local trial conducted before. Thus, in routine SGLT2 and ARNI are given to control glycemic level and maintain cardiac functioning. However, addition of Empagliflozin and Dapagliflozin can be more beneficial in improving cardiac functioning and reducing adverse events. Therefore the investigators planned to conduct this study to get evidence in local population. This will help to improve practice.

Connect with a study center

  • Shaikh Zayed Hospital

    Lahore, Punjab 54600
    Pakistan

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.